Literature DB >> 25557754

Effects of weight loss via high fat vs. low fat alternate day fasting diets on free fatty acid profiles.

Krista A Varady1, Vi T Dam2, Monica C Klempel3, Matthew Horne2, Rani Cruz2, Cynthia M Kroeger1, Sylvia Santosa2.   

Abstract

Cardiovascular disease risk is associated with excess body weight and elevated plasma free fatty acid (FFA) concentrations. This study examines how an alternate-day fasting (ADF) diet high (HF) or low (LF) in fat affects plasma FFA profiles in the context of weight loss, and changes in body composition and lipid profiles. After a 2-week weight maintenance period, 29 women (BMI 30-39.9 kg/m(2)) 25-65 years old were randomized to an 8-week ADF-HF (45% fat) diet or an ADF-LF (25% fat) diet with 25% energy intake on fast days and ad libitum intake on feed days. Body weight, BMI and waist circumference were assessed weekly and body composition was measured using dual x-ray absorptiometry (DXA). Total and individual FFA and plasma lipid concentrations were measured before and after weight loss. Body weight, BMI, fat mass, total cholesterol, LDL-C and triglyceride concentrations decreased (P < 0.05) in both groups. Total FFA concentrations also decreased (P < 0.001). In the ADF-LF group, decreases were found in several more FFAs than in the ADF-HF group. In the ADF-HF group, FFA concentrations were positively correlated with waist circumference. Depending on the macronutrient composition of a diet, weight loss with an ADF diet decreases FFA concentrations through potentially different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25557754      PMCID: PMC5378987          DOI: 10.1038/srep07561

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Risk of cardiovascular disease (CVD) has been associated with elevated plasma free fatty acid (FFA) concentrations12. Higher FFA concentrations in plasma have been associated with atherosclerosis, thrombosis and hypertension134. Moreover, fatty acid composition has been shown to affect disease risk. For example, high proportions of palmitic acid (16:0) have been associated with higher triglycerides, low density lipoprotein cholesterol (LDL-C), and total cholesterol56. Both expansion of adipose tissue and reduced FFA clearance contribute to elevated FFA concentrations commonly seen in obesity7. Weight loss through caloric restriction has been found to reduce many of the risk factors of CVD8910. However, the effects of weight loss on plasma FFA concentrations are unclear. Some studies have found no differences1112, while others have observed decreases1314 in FFA concentrations as a result of weight loss. The varied results of weight loss on FFA concentrations may depend on the dietary protocol and macronutrient distribution. Alternate day fasting (ADF) has been shown to be effective for weight loss. ADF regimens include alternating days of food consumption (feed days) with fast days where food intake is restricted to 25% of a person's energy needs in a day. Weight loss via ADF in adults has resulted in several cardioprotective changes in the blood lipid profile including lower LDL cholesterol, and increased average LDL particle size151617. Whether these ADF-associated changes in weight loss extend to changes in plasma total FFA and FFA composition is unknown. Additionally, we do not know how the macronutrient composition of ADF diets impact the FFA profile. The objective of this study is to examine how ADF diets of different macronutrient compositions affect plasma FFA profiles in the context of weight loss, and changes in body composition and lipid profiles.

Results

Subjects

Of the 35 women who started the study, 29 completed the trial. One subject was excluded due to scheduling conflicts and five subjects were excluded due to not having lost any weight during the weight loss period or noncompliance to the diet regime (n = 2 in the ADF-HF group and n = 3 in the ADF-LF group). Baseline characteristics of the ADF-HF and ADF-LF groups are reported in Table 1. The groups were well matched for age, BMI and body composition.
Table 1

Participant characteristics before (week 3) and after (week 10) the weight loss period

GroupADF-LF (n = 15)ADF-HF (n = 14)
TimeWeek 3Week 10Week 3Week 10
Age (y)43.2 ± 2.342.4 ± 3.0
Body weight (kg)88.0 ± 3.083.7 ± 2.7a89.2 ± 2.884.5 ± 2.7a
Body mass index (kg/m2)34.4 ± 0.832.7 ± 0.7a34.6 ± 0.732.8 ± 0.7a
% Fat41.6 ± 1.141.8 ± 1.140.4 ± 0.839.2 ± 1.0
Fat mass (kg)36.9 ± 1.935.4 ± 1.9a36.1 ± 1.433.2 ± 1.5a
Waist circumference98.4 ± 1.990.4 ± 2.3a98.0 ± 1.990.8 ± 1.9a
Total cholesterol (mmol/L)5.0 ± 0.24.2 ± 0.2a5.0 ± 0.34.3 ± 0.2a
LDL cholesterol (mmol/L)3.0 ± 0.22.3 ± 0.2a2.8 ± 0.22.3 ± 0.2a
HDL cholesterol (mmol/L)1.5 ± 0.11.5 ± 0.11.6 ± 0.11.6 ± 0.1
Triglycerides (mmol/L)1.1 ± 0.10.9 ± 0.1a1.4 ± 0.21.3 ± 0.2a
Glucose (mg/dL)107.4 ± 2.9105.1 ± 2.0108.4 ± 3.0105.7 ± 2.2

Values reported as mean ± SEM. Alternate day fasting high fat diet (ADF-HF); alternate day fasting low fat diet (ADF-LF).

aP < 0.05 within group difference (from week 3 to week 10).

Weight loss, body composition and plasma lipid concentrations

During the initial weight maintenance period (week 1–2), no between-group differences were found in any of the baseline characteristics. Over the 8-week ADF diet period, both the ADF-HF and the ADF-LF groups decreased (P < 0.05) in weight, BMI, fat mass, and waist circumference WC (Table 1). There were no differences in the extent of weight loss, changes in BMI, and WC between groups. There was a trend (P = 0.09) for a group*time interaction in fat mass. Total cholesterol, LDL-C, and triglycerides decreased in both groups (P < 0.05) during the weight loss period, whereas HDL-C did not change over time. There was a trend (P = 0.08) for a group*time interaction in LDL-C whereby a larger decrease in LDL-C was observed in the ADF-LF vs. the ADF-HF group.

FFA concentrations

With weight loss, total FFAs decreased (P < 0.001) in the ADF-LF group by an average of 98.62 ± 3.66 μmol/L. A trend was found (P = 0.05) in the ADF-HF group, where total FFA decreased by 53.93 ± 3.73 μmol/L (Figure 1). Changes in total FFA concentrations did not differ between groups. Significant decreases were observed in LNA (P = 0.01), MA (P = 0.049), AA (P = 0.007), LA (P = 0.004), PA (P = 0.001) and OA (P = 0.001) in the ADF-LF group (Table 2). In contrast, in the ADF-HF group there were significant reductions in FFA concentrations of LNA (P = 0.02) and LA (P = 0.048).
Figure 1

Total FFAs in ADF groups from week 3 to week 10.

Mean total fatty acid concentrations in ADF-HF and ADF-LF groups for weeks 3 and 10 of the study. Values reported as mean ± SEM. Alternate day fasting high fat diet (ADF-HF); alternate day fasting low fat diet (ADF-LF).

Table 2

FFA changes during an ADF-LF and ADF-HF weight loss diet

 ADF-LFADF-HF
FFA (μmol/L)Week 3Week 10Week 3Week 10
LNA11.08 ± 0.3110.96 ± 0.22a12.07 ± 0.3811.59 ± 0.29a
DHA11.61 ± 0.2111.36 ± 0.3112.01 ± 0.2511.59 ± 0.30
MA19.79 ± 0.5119.15 ± 0.46a20.72 ± 0.4620.14 ± 0.48
AA11.88 ± 0.3811.34 ± 0.34a12.67 ± 0.4212.50 ± 0.28
LA79.92 ± 2.9875.02 ± 3.47a89.39 ± 5.4285.10 ± 3.38a
PA48.35 ± 5.2139.99 ± 5.85b60.75 ± 6.4160.00 ± 5.56
OA37.71 ± 3.9531.47 ± 4.26b46.10 ± 4.1045.14 ± 3.60
Total FFA260.89 ± 22.69162.27 ± 24.35b264.14 ± 27.89210.21 ± 24.16

α-linolenic acid (LNA), docosahexanoic acid (DHA), myristic acid (MA), arachadonic acid (AA), linoleic acid (LA), palmitic acid (PA) and oleic acid (OA).

Values reported as mean ± SEM. Alternate day fasting high fat diet (ADF-HF); alternate day fasting low fat diet (ADF-LF).

aP < 0.05 within group difference (from week 3 to week 10).

bP < 0.001 within group difference.

Relationship between changes in body composition and FFA concentrations

Overall, a decrease in weight correlated with a decrease in MA (r = 0.391; P = 0.039). In the ADF-LF group weight loss correlated with decreases in DHA (r = 0.642; P = 0.013). In the ADF-HF group, lower fat mass correlated with decreases in LA (r = 0.635; P = 0.015). Changes in waist circumference in the ADF-HF group correlated with changes in LNA (r = 0.554; P = 0.040), LA (r = 0.700; P = 0.005), PA (r = 0.623; P = 0.017), OA (r = 0.610; P = 0.027), and total FFA (r = 0.623; P = 0.017) (Figure 2). No correlation was found between waist circumference and any FFA in the ADF-LF group.
Figure 2

Relationship between decreases in waist circumference (WC) and changes in α-linolenic acid (LNA; Panel a), linoleic acid (LA; Panel b), palmitic acid (PA; Panel c), and oleic acid (OA; Panel b).

Each panel shows a significant relationship (P < 0.05) between changes in WC and the FFA with an ADF-HF diet. There were no relationships between changes in WC and FFAs with an ADF-LF diet.

Relationship between changes in FFA and lipid concentrations

In the ADF-HF group, changes in LNA concentrations negatively correlated with total cholesterol (r = −0.601; P = 0.023) and HDL (r = −0.548; P = 0.042). In the ADF-HF group, DHA negatively correlated (r = −0.573; P = 0.032) with LDL-C. In the ADF-LF group, LA was positively correlated (r = 0.508; P = 0.044) with HDL-C.

Discussion

Elevated total and individual plasma FFA concentrations observed in obesity have been linked with cardiovascular disease risk125. During weight loss, diet composition may affect FFA concentrations67. Our study examined the effect of weight loss with a high fat ADF diet on total and individual FFA concentrations compared to a low fat ADF diet. We found that after weight loss, both groups had decreases in total FFA concentrations. However, even though weight loss and regional body composition results were similar between the two groups, almost all FFAs in the ADF-LF group decreased whereas changes were only noted in LA and LNA in the ADF-HF group. Despite similar changes in waist circumference, decreases in WC were correlated with decreases in several individual FFAs in the ADF-HF group only. In our study, we evaluated circulating concentrations of FFA. Elevated total and individual plasma FFA concentrations observed in obesity have been linked with cardiovascular disease risk and atherosclerosis151819. FFAs has been observed to impair vasodilation in blood vessels through activating apoptosis in the endothelium20. Furthermore, FFA is the main energy source for the myocardium; high levels of FFA play a role in damaging the myocardium, exacerbating heart failure and leading to myocardial infarction21. Thus far, no ADF studies have analysed circulating FFA profiles in order to determine whether any cardio-protective changes occur at the FFA level. The results of our FFA analysis show that weight loss with an ADF diet decreases total FFA concentrations, and that both the ADF-LF and ADF-HF diets could be effective at reducing FFA concentrations. Though no significant group*time interactions were observed, the decrease in total FFA concentrations with an ADF-LF diet was almost 2 times that of the ADF-HF diet. Previously, effects of weight loss on FFA concentrations appear to be variable with some studies showing decreases in FFA111314, while others show no change222324 or even increases252627 in FFA. Some of these studies achieved weight loss using a very low calorie diet, surgery or hypocaloric diets with varying macronutrient composition. Therefore, the dietary regimen used in these studies during the weight loss period may be a source of variability in changes of FFA to weight loss. Individual FFA concentrations have been shown to contribute to CVD risk differently. Thrombosis and arrhythmia have been associated with a number of saturated FFA including palmitic acid2829. Palmitic, oleic, and myristic acid have been positively associated with lipid risk factors of CVD6. Our study also showed that LA, DHA and LNA were associated with lipid risk factors of CVD. Patients post-myocardial infarction were also shown to have greater palmitic and oleic acid and lower linoleic acid compared to age-matched controls30. With an ADF-LF diet, we observed a significant reduction in more types of FFAs (LNA, MA, AA, LA, PA and OA) vs. in the ADF-HF group (LNA and LA). This suggests that the low fat ADF diet was more effective at decreasing FFA concentrations vs. the high fat ADF diet. To our knowledge this is the first study to examine changes in individual FFA composition in the context of a weight loss program using ADF with varying macronutrient composition. Normal weight participants who consumed a high fat diet also observed changes in the proportion of LA and LNA compared with a low fat diet31. These results suggest that LA and LNA are more sensitive to changes with the consumption of a high fat diet. Therefore, combining a high fat diet with weight loss via an ADF protocol would likely have a greater effect on these FFAs, as observed in this study. There were strong correlations in the ADF-HF group where decreases in waist circumference were associated with decreases in several FFAs. In contrast, there were no such correlations between waist circumference and FFAs in the ADF-LF group. Waist circumference is considered a surrogate marker of abdominal adiposity and visceral fat mass32. We hypothesize that in weight loss, the levels of dietary fat intake and changes in abdominal fat have a collective effect on decreases in FFA concentrations. The relatively larger contribution of a diet low in fat to changes in FFA concentrations may mask the relationship between abdominal fat mass and FFA concentrations. In contrast, weight loss with a high fat diet may have a smaller effect in lowering FFA concentrations in comparison to the greater effect of decreases in abdominal fat. Regardless of the relative contribution of dietary fat content on FFA lowering, changes in abdominal fat mass during weight loss with an ADF diet resulted in cardioprotective changes in FFA concentrations. A major strength of the study was that both the ADF-LF and ADF-HF group were matched for body composition. Additionally, body composition changed equally in the ADF-LF and ADF-HF groups. Thus, the effects of a HF and LF diet on FFA concentrations could be examined without the confounding effects of changes in body composition. Additionally, since all the meals were provided and the ratio of SFA:MUFA:PUFA was similar in the high and low fat diets, the effects of overall fat content on FFA concentrations could be isolated. Due to a communication error during sample processing, hormonal regulators of lipolysis were not measured. While insulin inhibits FFA release, other hormones such as epinephrine stimulate FFA release over a wide range3334. Thus, we are not able to determine the mechanisms that underlie the changes we saw in FFA composition as a result of a ADF-HF or ADF-LF diet. Another limitation of this study was that both intervention groups lost weight during the weight maintenance period. However, there were no between group differences in weight changes. It is conceivable that decreases in weight during the weight maintenance period diluted observable decreases in FFA concentrations during the weight loss that followed. As we observed significant changes in FFA concentrations during the weight loss period, the effect of the initial weight lost during the weight maintenance period on FFA concentrations was likely to be minimal. In summary, our findings are the first to demonstrate that a weight loss intervention with ADF-HF or ADF-LF can reduce total and individual plasma FFA concentrations though it appears that a LF diet may be more effective at lowering FFA. Though both diets equally reduced waist circumference, we found several strong correlations between WC and changes in individual FFAs in the ADF-HF group that were not present in the ADF-LF group. Since there were no differences in changes in FFA composition between groups, the correlations between WC and FFAs found only in the ADF-HF group imply that ADF-HF and ADF-LF diets may lower FFA concentrations through different mechanisms. Overall, the decreases in FFA concentrations after ADF weight loss may be cardio-protective. Future studies might include individual FFA profiles when evaluating macronutrient composition, as the effects of specific FFAs in this context are not well known.

Methods

Participants were recruited from the Chicago area and were randomized by stratified random sampling based on BMI and age. Subjects were then randomized to a ADF-HF or ADF-LF group, as previously described35. Briefly, potential participants were eligible if they were female, 25 to 65 years of age, with a body mass index (BMI) between 30 and 39.9 kg/m2. Participants had to be weight stable for 3 months prior to the beginning of the study, sedentary or lightly active, non-smokers, non-diabetic, and not taking any medications. Postmenopausal women were included provided they maintained a stable dose of their current hormone replacement therapy. All volunteers provided written informed consent. All study protocols were carried our in accordance with guidelines approved by the Office for the Protection of Research Subjects at the University of Illinois at Chicago, Chicago, USA and the Human Research Ethics Committee at Concordia University, Montreal, Canada.

Diet

Food provided was prepared in the metabolic kitchen of the Human Nutrition Research Unit at the University of Illinois, Chicago. All subjects underwent a 2-week high fat or low fat weight maintenance period (week 1–2), followed by an 8-week ADF weight-loss diet (week 3–10). The ADF-HF group received 45% fat (14% saturated fat, 20% monounsaturated fat, 11% polyunsaturated fat) and the ADF-LF group received 25% fat (6% saturated fat, 13% monounsaturated, 6% polyunsaturated fat). A detailed description of the diet composition and energy requirements is provided elsewhere35. Subjects were provided with 3 meals on each feed day and one meal on each fast day. All subjects were asked to consume their meals at the same time each day.

Weight loss and body composition

Body weight measurements were taken weekly following an overnight fast (to the nearest 0.5 kg) in light clothing and without shoes using a balance beam scale (HealthOMeter; Sunbeam Products, Boca Raton, FL). Height was measured using a wall-mounted stadiometer (to the nearest 0.1 cm). BMI was assessed as kg/m2. Total fat mass and fat-free mass was determined by dual energy X-ray absorptiometry (DXA) (QDR 4500 W, Hologic Inc. Arlington, MA) at baseline, week 3 and week 10. Waist circumference was taken by a flexible measuring tape (to the nearest 0.1 cm), midway between the lower costal margin and super iliac crest during a period of expiration. Participants wore a pedometer (Digi-Walker SW-200, Yamax Corp., Japan) during the study to ensure maintenance of regular physical activity habits.

Plasma lipid and free fatty acid analysis

Blood samples were collected in the morning after an overnight fast at baseline, week 3 and week 10. Exercise, alcohol, and coffee were restricted for 24 h before each visit. Blood was centrifuged for 10 min at 520 G in 4°C and plasma was stored at −80°C until analyzed. Plasma lipid samples were analysed as previously described35. FFA were quantified via ultra performance liquid chromatography (UPLC) (Waters ACUITY UPLC, Milford, Massachusetts). α-linolenate (LNA), docosahexanoate (DHA), arachadonate (AA), and linoleate (LA) standards were purchased from Sigma-Aldrich. Myristate (MA), palmitate (PA) and oleate (OA) standards were purchased from Nu-Check prep. All standards were >99% pure. FFA standards were dissolved in 4% fatty acid free albumin phosphate buffer. The individual standard solutions were combined to form an external mixed FFA standard. D31 palmitate (Cambridge Isotope Laboratories, Inc., Tewksbury, Massachusetts) was used as an internal standard and added to plasma samples and external standards. Plasma samples and the mixed FFA standards were extracted and derivatized as previously described36. Samples were then transferred to a UPLC vial in 20:80 H2O:acetonitrile solution and 10 μL were injected onto a 55°C heated Acquity UPLC BEH C18 1.7 μM 2.1 × 150 mm column eluted with H2O:acetonitrile 20:80 at a mL/min rate. Peaks were detected with a photodiode array (PDA) detector at 242 nm.

Statistical methods

All data was analyzed using SPSS software (version 20.0, SPSS Inc., Chicago, IL). Results are presented as mean ± SEM. Normality was assessed by Shapiro-Wilks tests. Independent samples t-tests were used to test baseline differences between groups. Repeated-measures ANOVA were used to assess for significant differences with time as the within-subject factor and diet as the between-subject factor. Post-hoc analyses were done using a Tukey's test. Pearson correlations were performed to assess the relationships between body composition and FFA concentrations. Differences were considered significant at P < 0.05.

Additional information

Funding source PERFORM Seed Funding, Concordia University, NSERCDiscovery Grant, University of Illinois at Chicago, Department of Kinesiology and Nutrition, Departmental funding. SS is also the recipient of a Canada Research Chair, Tier II in Clinical Nutrition. Funding sources were not involved in the study design, collection, and analysis/interpretation of data in the writing of the manuscript or in the decision to submit the article for publication.
  36 in total

1.  Total fat intake modifies plasma fatty acid composition in humans.

Authors:  S K Raatz; D Bibus; W Thomas; P Kris-Etherton
Journal:  J Nutr       Date:  2001-02       Impact factor: 4.798

2.  Prognostic usefulness of free fatty acids in patients with stable coronary heart disease.

Authors:  Lutz P Breitling; Dietrich Rothenbacher; Norma C Grandi; Winfried März; Hermann Brenner
Journal:  Am J Cardiol       Date:  2011-05-31       Impact factor: 2.778

Review 3.  Interaction between free fatty acids and glucose metabolism.

Authors:  Guenther Boden
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2002-09       Impact factor: 4.294

Review 4.  Physiological regulation of NEFA availability: lipolysis pathway.

Authors:  V Stich; M Berlan
Journal:  Proc Nutr Soc       Date:  2004-05       Impact factor: 6.297

5.  Lipolysis during fasting. Decreased suppression by insulin and increased stimulation by epinephrine.

Authors:  M D Jensen; M W Haymond; J E Gerich; P E Cryer; J M Miles
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

6.  Sex differences in the relation of visceral adipose tissue accumulation to total body fatness.

Authors:  S Lemieux; D Prud'homme; C Bouchard; A Tremblay; J P Després
Journal:  Am J Clin Nutr       Date:  1993-10       Impact factor: 7.045

7.  A microfluorometric method for the determination of free fatty acids in plasma.

Authors:  J Miles; R Glasscock; J Aikens; J Gerich; M Haymond
Journal:  J Lipid Res       Date:  1983-01       Impact factor: 5.922

8.  Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults.

Authors:  Krista A Varady; Surabhi Bhutani; Emily C Church; Monica C Klempel
Journal:  Am J Clin Nutr       Date:  2009-09-30       Impact factor: 7.045

9.  Fasting nonesterified fatty acid profiles in childhood and their relationship with adiposity, insulin sensitivity, and lipid levels.

Authors:  Matthew A Sabin; Mark De Hora; Jeff M P Holly; Linda P Hunt; Anna L Ford; Simon R Williams; Julien S Baker; Christopher J Retallick; Elizabeth C Crowne; Julian P H Shield
Journal:  Pediatrics       Date:  2007-12       Impact factor: 7.124

10.  The effects of modified alternate-day fasting diet on weight loss and CAD risk factors in overweight and obese women.

Authors:  Samira Eshghinia; Fatemeh Mohammadzadeh
Journal:  J Diabetes Metab Disord       Date:  2013-01-09
View more
  15 in total

1.  Adipose Insulin Resistance in Obese Adolescents Across the Spectrum of Glucose Tolerance.

Authors:  Karen Hershkop; Omri Besor; Nicola Santoro; Bridget Pierpont; Sonia Caprio; Ram Weiss
Journal:  J Clin Endocrinol Metab       Date:  2016-04-07       Impact factor: 5.958

Review 2.  Time-Restricted Eating, Intermittent Fasting, and Fasting-Mimicking Diets in Weight Loss.

Authors:  Maura Fanti; Amrendra Mishra; Valter D Longo; Sebastian Brandhorst
Journal:  Curr Obes Rep       Date:  2021-01-29

Review 3.  Impact of intermittent fasting on health and disease processes.

Authors:  Mark P Mattson; Valter D Longo; Michelle Harvie
Journal:  Ageing Res Rev       Date:  2016-10-31       Impact factor: 10.895

4.  Intermittent and periodic fasting, longevity and disease.

Authors:  Valter D Longo; Maira Di Tano; Mark P Mattson; Novella Guidi
Journal:  Nat Aging       Date:  2021-01-14

5.  Intermittent Energy Restriction for Weight Loss: A Systematic Review of Cardiometabolic, Inflammatory and Appetite Outcomes.

Authors:  Xueting Wei; Ashley Cooper; Irene Lee; Christine A Cernoch; Ginny Huntoon; Brandi Hodek; Hanna Christian; Ariana M Chao
Journal:  Biol Res Nurs       Date:  2022-05-08       Impact factor: 2.318

6.  Intermittent fasting and weight loss: Systematic review.

Authors:  Stephanie Welton; Robert Minty; Teresa O'Driscoll; Hannah Willms; Denise Poirier; Sharen Madden; Len Kelly
Journal:  Can Fam Physician       Date:  2020-02       Impact factor: 3.275

Review 7.  Intermittent Energy Restriction, Weight Loss and Cardiometabolic Risk: A Critical Appraisal of Evidence in Humans.

Authors:  Alexia L Katsarou; Nicholas L Katsilambros; Chrysi C Koliaki
Journal:  Healthcare (Basel)       Date:  2021-04-22

Review 8.  Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting.

Authors:  Stephen D Anton; Keelin Moehl; William T Donahoo; Krisztina Marosi; Stephanie A Lee; Arch G Mainous; Christiaan Leeuwenburgh; Mark P Mattson
Journal:  Obesity (Silver Spring)       Date:  2017-10-31       Impact factor: 5.002

9.  Effect of Bariatric Weight Loss on the Adipose Lipolytic Transcriptome in Obese Humans.

Authors:  Shakun Karki; Melissa G Farb; Samantha Myers; Caroline Apovian; Donald T Hess; Noyan Gokce
Journal:  Mediators Inflamm       Date:  2015-11-18       Impact factor: 4.711

10.  Intermittent Fasting (Alternate Day Fasting) in Healthy, Non-obese Adults: Protocol for a Cohort Trial with an Embedded Randomized Controlled Pilot Trial.

Authors:  Norbert J Tripolt; Slaven Stekovic; Felix Aberer; Jasmin Url; Peter N Pferschy; Sabrina Schröder; Nicolas Verheyen; Albrecht Schmidt; Ewald Kolesnik; Sophie H Narath; Regina Riedl; Barbara Obermayer-Pietsch; Thomas R Pieber; Frank Madeo; Harald Sourij
Journal:  Adv Ther       Date:  2018-07-25       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.